HMGCR and non-small cell lung carcinoma: The enzyme 3‐hydroxy‐3‐methylglutaryl‐CoA reductase (HMGCR), which is elevated in human NSCLC tissues, becomes a therapeutic target as its inhibition by fluvastatin curtails tumourigenesis of NSCLC by abating tumour proliferation and promoting apoptosis of cancer cells [18].